Cargando…

Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases

Merging pharmaceutical and digital (mobile health, mHealth) ingredients to create new therapies for chronic diseases offers unique opportunities for natural products such as omega-3 polyunsaturated fatty acids (n-3 PUFA), curcumin, resveratrol, theanine, or α-lipoic acid. These compounds, when combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulaj, Grzegorz, Ahern, Margaret M., Kuhn, Alexis, Judkins, Zachary S., Bowen, Randy C., Chen, Yizhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011401/
https://www.ncbi.nlm.nih.gov/pubmed/27262323
http://dx.doi.org/10.2174/1574884711666160603012237
_version_ 1782451823216427008
author Bulaj, Grzegorz
Ahern, Margaret M.
Kuhn, Alexis
Judkins, Zachary S.
Bowen, Randy C.
Chen, Yizhe
author_facet Bulaj, Grzegorz
Ahern, Margaret M.
Kuhn, Alexis
Judkins, Zachary S.
Bowen, Randy C.
Chen, Yizhe
author_sort Bulaj, Grzegorz
collection PubMed
description Merging pharmaceutical and digital (mobile health, mHealth) ingredients to create new therapies for chronic diseases offers unique opportunities for natural products such as omega-3 polyunsaturated fatty acids (n-3 PUFA), curcumin, resveratrol, theanine, or α-lipoic acid. These compounds, when combined with pharmaceutical drugs, show improved efficacy and safety in preclinical and clinical studies of epilepsy, neuropathic pain, osteoarthritis, depression, schizophrenia, diabetes and cancer. Their additional clinical benefits include reducing levels of TNFα and other inflammatory cytokines. We describe how pleiotropic natural products can be developed as bioactive incentives within the network pharmacology together with pharmaceutical drugs and self-care interventions. Since approximately 50% of chronically-ill patients do not take pharmaceutical drugs as prescribed, psychobehavioral incentives may appeal to patients at risk for medication non-adherence. For epilepsy, the incentive-based network therapy comprises anticonvulsant drugs, antiseizure natural products (n-3 PUFA, curcumin or/and resveratrol) coupled with disease-specific behavioral interventions delivered by mobile medical apps. The add-on combination of antiseizure natural products and mHealth supports patient empowerment and intrinsic motivation by having a choice in self-care behaviors. The incentivized therapies offer opportunities: (1) to improve clinical efficacy and safety of existing drugs, (2) to catalyze patient-centered, disease self-management and behavior-changing habits, also improving health-related quality-of-life after reaching remission, and (3) merging copyrighted mHealth software with natural products, thus establishing an intellectual property protection of medical treatments comprising the natural products existing in public domain and currently promoted as dietary supplements. Taken together, clinical research on synergies between existing drugs and pleiotropic natural products, and their integration with self-care, music and mHealth, expands precision/personalized medicine strategies for chronic diseases via pharmacological-behavioral combination therapies.
format Online
Article
Text
id pubmed-5011401
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-50114012016-09-20 Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases Bulaj, Grzegorz Ahern, Margaret M. Kuhn, Alexis Judkins, Zachary S. Bowen, Randy C. Chen, Yizhe Curr Clin Pharmacol Article Merging pharmaceutical and digital (mobile health, mHealth) ingredients to create new therapies for chronic diseases offers unique opportunities for natural products such as omega-3 polyunsaturated fatty acids (n-3 PUFA), curcumin, resveratrol, theanine, or α-lipoic acid. These compounds, when combined with pharmaceutical drugs, show improved efficacy and safety in preclinical and clinical studies of epilepsy, neuropathic pain, osteoarthritis, depression, schizophrenia, diabetes and cancer. Their additional clinical benefits include reducing levels of TNFα and other inflammatory cytokines. We describe how pleiotropic natural products can be developed as bioactive incentives within the network pharmacology together with pharmaceutical drugs and self-care interventions. Since approximately 50% of chronically-ill patients do not take pharmaceutical drugs as prescribed, psychobehavioral incentives may appeal to patients at risk for medication non-adherence. For epilepsy, the incentive-based network therapy comprises anticonvulsant drugs, antiseizure natural products (n-3 PUFA, curcumin or/and resveratrol) coupled with disease-specific behavioral interventions delivered by mobile medical apps. The add-on combination of antiseizure natural products and mHealth supports patient empowerment and intrinsic motivation by having a choice in self-care behaviors. The incentivized therapies offer opportunities: (1) to improve clinical efficacy and safety of existing drugs, (2) to catalyze patient-centered, disease self-management and behavior-changing habits, also improving health-related quality-of-life after reaching remission, and (3) merging copyrighted mHealth software with natural products, thus establishing an intellectual property protection of medical treatments comprising the natural products existing in public domain and currently promoted as dietary supplements. Taken together, clinical research on synergies between existing drugs and pleiotropic natural products, and their integration with self-care, music and mHealth, expands precision/personalized medicine strategies for chronic diseases via pharmacological-behavioral combination therapies. Bentham Science Publishers 2016-05 2016-05 /pmc/articles/PMC5011401/ /pubmed/27262323 http://dx.doi.org/10.2174/1574884711666160603012237 Text en © 2016 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Bulaj, Grzegorz
Ahern, Margaret M.
Kuhn, Alexis
Judkins, Zachary S.
Bowen, Randy C.
Chen, Yizhe
Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
title Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
title_full Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
title_fullStr Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
title_full_unstemmed Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
title_short Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
title_sort incorporating natural products, pharmaceutical drugs, self-care and digital/mobile health technologies into molecular-behavioral combination therapies for chronic diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011401/
https://www.ncbi.nlm.nih.gov/pubmed/27262323
http://dx.doi.org/10.2174/1574884711666160603012237
work_keys_str_mv AT bulajgrzegorz incorporatingnaturalproductspharmaceuticaldrugsselfcareanddigitalmobilehealthtechnologiesintomolecularbehavioralcombinationtherapiesforchronicdiseases
AT ahernmargaretm incorporatingnaturalproductspharmaceuticaldrugsselfcareanddigitalmobilehealthtechnologiesintomolecularbehavioralcombinationtherapiesforchronicdiseases
AT kuhnalexis incorporatingnaturalproductspharmaceuticaldrugsselfcareanddigitalmobilehealthtechnologiesintomolecularbehavioralcombinationtherapiesforchronicdiseases
AT judkinszacharys incorporatingnaturalproductspharmaceuticaldrugsselfcareanddigitalmobilehealthtechnologiesintomolecularbehavioralcombinationtherapiesforchronicdiseases
AT bowenrandyc incorporatingnaturalproductspharmaceuticaldrugsselfcareanddigitalmobilehealthtechnologiesintomolecularbehavioralcombinationtherapiesforchronicdiseases
AT chenyizhe incorporatingnaturalproductspharmaceuticaldrugsselfcareanddigitalmobilehealthtechnologiesintomolecularbehavioralcombinationtherapiesforchronicdiseases